A case for the use of chemotherapy in hereditary mitochondrial optic neuropathies: Successful administration of cisplatin/etoposide in a male patient with testicular seminoma and Leber's hereditary optic neuropathy

Jean-Luc Vrisakis; Clare L Fraser; Adel Shahnam; Udit Nindra; Peter Grimison

doi:10.1002/ccr3.9045

A case for the use of chemotherapy in hereditary mitochondrial optic neuropathies: Successful administration of cisplatin/etoposide in a male patient with testicular seminoma and Leber's hereditary optic neuropathy

Clin Case Rep. 2024 Jul 8;12(7):e9045. doi: 10.1002/ccr3.9045. eCollection 2024 Jul.

Authors

Jean-Luc Vrisakis¹, Clare L Fraser^{2

3}, Adel Shahnam⁴, Udit Nindra⁵, Peter Grimison^{6

7}

Affiliations

¹ Department of Medicine Royal Prince Alfred Hospital Sydney New South Wales Australia.
² Department of Medicine and Health, Save Sight Institute University of Sydney Sydney New South Wales Australia.
³ Department of Ophthalmology Sydney and Sydney Eye Hospital Sydney New South Wales Australia.
⁴ Peter MacCallum Cancer Centre Melbourne Victoria Australia.
⁵ Cancer Therapy Centre Liverpool Hospital Sydney New South Wales Australia.
⁶ Department of Medical Oncology Chris O'Brien Lifehouse Sydney New South Wales Australia.
⁷ Department of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales Australia.

Abstract

We report on the successful use of chemotherapy for treatment of stage 2B testicular seminoma in a carrier of the Leber's hereditary optic neuropathy 11778 mitochondrial mutation. Neurotoxic chemotherapy may not prompt disease conversion.

Keywords: antineoplastic agents; optic atrophy, hereditary, Leber; seminoma.

Publication types

Case Reports